Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Structure of the platelet glycoprotein Ib receptor in complex with a novel antithrombotic agent

Jing Wang, Yongxiang Gao, Lan Chen, Yugang Guo, Siyi Hu, Liansheng Cheng, Weihua Xiao, Jiyuan Ke, Zhongliang Zhu, Liwen Niu

Blood (2021) 137 (6): 844–847.

https://doi.org/10.1182/blood.2020008028

Published: 2021

Includes: Supplemental data

Journal Articles

Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma

Debra Hoppensteadt, PhD, Emily Bontekoe, Fakiha Siddiqui, Ambar Farooqui, Omer Iqbal, MD, Walter Jeske, PhD, Jeanine Walenga, PhD, Alfonso J Tafur, MD MS, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 3374.

https://doi.org/10.1182/blood-2019-131221

Published: 2019

Journal Articles

Characterisation of Citrullinated TFPI and Truncated TFPI Constructs By PAD4 in Model and Plasma Systems

M.G.L. Christella D. Thomassen, Dennis P.L. Suylen, Tilman M. Hackeng, PhD, Rory R. Koenen, PhD

Blood (2019) 134 (Supplement_1): 2390.

https://doi.org/10.1182/blood-2019-131190

Published: 2019

Journal Articles

Yearly Percent Incidence of Suspected Novel Oral Anticoagulant Interference on Thrombophilia Testing: A Nine Year Experience at a Reference Coagulation Laboratory

Edward C.C. Wong, MD MA, Laura A. Worfolk, PhD, Jeffrey S. Dlott, MD

Blood (2018) 132 (Supplement 1): 4819.

https://doi.org/10.1182/blood-2018-99-112972

Published: 2018

Journal Articles

To Test or Not to Test? Quantifying and Reducing Inappropriate Hypercoagulable Workups in the Inpatient Setting

Mariola Vazquez-Martinez, MD, Erika Correa, MD MS, Shaun Hanson, MD, Kathleen Degen, MD, Kevin D'Mello, MD, Kristine Ward, MD, Michael Styler, MD

Blood (2018) 132 (Supplement 1): 5819.

https://doi.org/10.1182/blood-2018-99-117183

Published: 2018

Journal Articles

Using Electronic Best Practice Alerts to Improve Thrombophilia Testing Based on ASH Choosing Wisely Guidelines

Tomi Jun, MD, Henry Kwang, MD, Eric Mou, MD, Caroline Berube, MD, Neil Shah, MD, Rajani Kaimal, MS, Jason Bentley, PhD, Neera Ahuja, MD, Lisa Shieh, MD, Jason Hom, MD

Blood (2017) 130 (Supplement 1): 3355.

https://doi.org/10.1182/blood.V130.Suppl_1.3355.3355

Published: 2017

Journal Articles

Direct Oral Anticoagulants in Anti-Phospholipid Syndrome

Houry Leblebjian, PharmD, Aric Parnes, MD

Blood (2017) 130 (Supplement 1): 2145.

https://doi.org/10.1182/blood.V130.Suppl_1.2145.2145

Published: 2017

Journal Articles

Centralized Laboratory Testing for Inhibitors in the U.S. Hemophilia Treatment Centers Network: Testing Protocol and Results on 10,178 Specimens

Connie H Miller, PhD, Dorothy Ellingsen, Jennifer Driggers, Brian Boylan, Amanda B. Payne, MPH, Fiona Bethea, MPH, Vanessa R Byams, MPH, J. Michael Soucie, PhD, Christopher J. Bean, PhD

Blood (2017) 130 (Supplement 1): 3692.

https://doi.org/10.1182/blood.V130.Suppl_1.3692.3692

Published: 2017

Journal Articles

Distinct Diagnostic and Clinical Features of Bone Marrow Mastocytosis: A Study of the Registry of the European Competence Network on Mastocytosis (ECNM)

Massimiliano Bonifacio, MD, Patrizia Bonadonna, MD, Hanneke Oude Elberink, MD, Björn van Anrooij, MD, Aleksandra Górska, MD, Magdalena Lange, MD, Emir Hadzijusufovic, DVM, Luigi Scaffidi, Ilaria Tanasi, MD, Cecelia Perkins, Virginia Valeria Ferretti, Anja Illerhaus, PhD, Thilo Jakob, MD, Roberta Parente, MD, Mohamad Jawhar, MD, Francesca Caroppo, MD, Alexander Zink, MD, Alex Kilbertus, MD, Akif Selim Yavuz, MD, Michael Doubek, MD PhD, Hans Hagglund, MD PhD, Jens P. Panse, MD, Vito Sabato, MD PhD, Elisabeth Aberer, MD, Nadja Jaekel, MD, Peter Vandenberghe, MD PhD, David Fuchs, MD, Knut Brockow, MD, Anna Belloni Fortina, MD, Andreas Reiter, MD, Massimo Triggiani, MD, Khalid Shoumariyeh, MD, Karin Hartmann, MD, Chiara Elena, Olivier Hermine, MD PhD, Jason Gotlib, MD, Marek Niedoszytko, MD, Hanneke Kluin-Nelemans, MD PhD, Wolfgang R. Sperr, MD, Peter Valent, MD, Roberta Zanotti, MD

Blood (2017) 130 (Supplement 1): 4200.

https://doi.org/10.1182/blood.V130.Suppl_1.4200.4200

Published: 2017

Journal Articles

Lupus Anticoagulant Testing in Patients Receiving Rivaroxaban or Apixaban for the Treatment of Venous Thromboembolism

Matthew R. Kovacs, Alejandro Lazo-Langner, MD MSc, FRCPC, Martha L Louzada, MD, Michael J. Kovacs, MD FRCPC

Blood (2016) 128 (22): 5017.

https://doi.org/10.1182/blood.V128.22.5017.5017

Published: 2016

Journal Articles

Dilute Russell Viper Venom Time Interpretation and Clinical Correlation: A Two-Year Retrospective Institutional Review

Cyril Jacquot, MDPhD, Geoffrey D. Wool, MD PhD, Scott C. Kogan, MD

Blood (2016) 128 (22): 2609.

https://doi.org/10.1182/blood.V128.22.2609.2609

Published: 2016

Journal Articles

Rapaport SI, Aas K, Owren PA. The clotting action of Russell viper venom. Blood . 1954;9(12): 1185-1194 .

Blood (2016) 127 (9): 1077.

https://doi.org/10.1182/blood-2016-01-692822

Published: 2016

Journal Articles

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors

Daniël Verhoef, Mark Schreuder, Ka Lei Cheung, Pieter H. Reitsma, Mettine H.A. Bos, PhD

Blood (2015) 126 (23): 126.

https://doi.org/10.1182/blood.V126.23.126.126

Published: 2015

Journal Articles

Efficacy of Lidocaine Patch in Relieving Severe Sickle Cell Leg Ulcer Pain

Clarisse Lopes de Castro Lobo, ASH, MEMBER, Ana Maria Mach Queiroz, MD, Agueda Gloria Sabino De Matos, Eleonora D'Avila Thome, Samir K. Ballas, MD

Blood (2015) 126 (23): 4596.

https://doi.org/10.1182/blood.V126.23.4596.4596

Published: 2015

Journal Articles

Recombinant FIX/X-Bp from the Japanese Habu Snake Is a Universal Ligand for Purification of Highly Carboxylated Factor IX Variants and Factor X

Oblaise Mercury, BS, Lucy Liu, PhD, Ayman Ismail, PhD, Ming Zhang, PhD, Qi Lu, PhD, Tom O Cameron, PhD, Allison Goodman, BS, Liz Culyba, PhD, Rahul Ravindran Nair, BS, MS, Amy M Holthaus, BS, MS, John Kulman, PhD, Robert Peters, PhD

Blood (2015) 126 (23): 1081.

https://doi.org/10.1182/blood.V126.23.1081.1081

Published: 2015

Journal Articles

Therapeutic Efficacy of Anfibatide in a Murine Model of Thrombotic Thrombocytopenic Purpura

Liang Zheng, PhD, Yingying Mao, PhD, Mandy Li, PhD, Xiangrong Dai, M.S., Benjamin Li, PhD, X. Long Zheng, MD PhD

Blood (2015) 126 (23): 659.

https://doi.org/10.1182/blood.V126.23.659.659

Published: 2015

Journal Articles

Primary Cutaneous γδ T-Cell Lymphoproliferative Disorder Following a Stingray Puncture: A Case Report

Chee Won Oh, MD PhD, Victor Prieto, MD, Xiao Ni, MD PhD, Madeleine Duvic, MD

Blood (2014) 124 (21): 4967.

https://doi.org/10.1182/blood.V124.21.4967.4967

Published: 2014

Journal Articles

Distinct Mechanism of Anti-Hemophilic FVIII Activation By Nascent FXa in the Tissue Factor-FVIIa Coagulation Initiation Complex Resistant to FXa-Directed Inhibition

Yuichi Kamikubo, PhD, Grazia Loredana Mendolicchio, MD PhD, Antonella Zampolli, PhD, Patrizia Marchese, PhD, Andrew J. Gale, PhD, Sriram Krishnaswamy, PhD, Andras Gruber, MD, Lars Christian Petersen, Wolfram Ruf, MD, Zaverio M Ruggeri, MD

Blood (2014) 124 (21): 2803.

https://doi.org/10.1182/blood.V124.21.2803.2803

Published: 2014

Journal Articles

Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants

Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, PhD, Josephine Cunanan, Omer Iqbal, MD, Jawed Fareed, Ph.D.

Blood (2013) 122 (21): 3642.

https://doi.org/10.1182/blood.V122.21.3642.3642

Published: 2013

Journal Articles

Novel Point-Of-Use FXa Assay For Monitoring Anticoagulant Therapy By Oral Factor Xa Inhibitors and Heparin

Nina Lukinova, Ph.D., Mano Venkatesan, Jill White

Blood (2013) 122 (21): 4816.

https://doi.org/10.1182/blood.V122.21.4816.4816

Published: 2013

NARROW

Structure of the platelet glycoprotein Ib receptor in complex with a novel antithrombotic agent

Prothrombinase Induced Clotting Time Is More Sensitive then aPTT and PT and Can be Used for the Monitoring of Anti-Xa Agents in Whole Blood and Plasma

Characterisation of Citrullinated TFPI and Truncated TFPI Constructs By PAD4 in Model and Plasma Systems

Yearly Percent Incidence of Suspected Novel Oral Anticoagulant Interference on Thrombophilia Testing: A Nine Year Experience at a Reference Coagulation Laboratory

To Test or Not to Test? Quantifying and Reducing Inappropriate Hypercoagulable Workups in the Inpatient Setting

Using Electronic Best Practice Alerts to Improve Thrombophilia Testing Based on ASH Choosing Wisely Guidelines

Direct Oral Anticoagulants in Anti-Phospholipid Syndrome

Centralized Laboratory Testing for Inhibitors in the U.S. Hemophilia Treatment Centers Network: Testing Protocol and Results on 10,178 Specimens

Distinct Diagnostic and Clinical Features of Bone Marrow Mastocytosis: A Study of the Registry of the European Competence Network on Mastocytosis (ECNM)

Lupus Anticoagulant Testing in Patients Receiving Rivaroxaban or Apixaban for the Treatment of Venous Thromboembolism

Dilute Russell Viper Venom Time Interpretation and Clinical Correlation: A Two-Year Retrospective Institutional Review

Rapaport SI, Aas K, Owren PA. The clotting action of Russell viper venom. Blood . 1954;9(12): 1185-1194 .

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors

Efficacy of Lidocaine Patch in Relieving Severe Sickle Cell Leg Ulcer Pain

Recombinant FIX/X-Bp from the Japanese Habu Snake Is a Universal Ligand for Purification of Highly Carboxylated Factor IX Variants and Factor X

Therapeutic Efficacy of Anfibatide in a Murine Model of Thrombotic Thrombocytopenic Purpura

Primary Cutaneous γδ T-Cell Lymphoproliferative Disorder Following a Stingray Puncture: A Case Report

Distinct Mechanism of Anti-Hemophilic FVIII Activation By Nascent FXa in the Tissue Factor-FVIIa Coagulation Initiation Complex Resistant to FXa-Directed Inhibition

Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants

Novel Point-Of-Use FXa Assay For Monitoring Anticoagulant Therapy By Oral Factor Xa Inhibitors and Heparin

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only